RTW Biotech Opportunities (RTW) has announced an investment in new portfolio company, Jade Biosciences.
RTW, alongside other investment vehicles managed by RTW Investments LP, participated in Jade’s financing round that raised $80m for its launch.
The funding will be used to support Jade’s plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.
Jade Biosciences is developing a pipeline of potentially best-in-class therapies to redefine the standard of care for patients living with autoimmune conditions. Jade’s pipeline of potentially best-in-class biologics was engineered by Paragon Therapeutics, which was founded by leading healthcare investor Fairmount. Jade is headquartered in Waltham, MA.
Andrew King, D.V.M., Ph.D., is Jade’s chief scientific officer. He brings more than 15 years of leadership experience across biotech and pharmaceutical industries, having previously served as chief scientific officer of Chinook Therapeutics, a clinical-stage biopharmaceutical company developing precision medicines for rare, severe chronic kidney diseases.
Jade is the fourth company founded from Paragon, which also includes Apogee Therapeutics, whose Series B the RTW also invested in and continues to hold in its core public portfolio segment.
